Tag: NSCLC

Pfizer Received FDA Approval for Avastin® Biosimilar

Pfizer Inc. today announced the United States (U.S.) Food and Drug Administration (FDA) has approved ZIRABEV™ (bevacizumab-bvzr), a biosimilar to Avastin® (bevacizumab), for the treatment of five type...

EС Approved Pfizer’s LORVIQUA®

Pfizer Inc. announced today that the European Commission (EC) granted conditional marketing authorization for LORVIQUA® (lorlatinib, available in the U.S., Canada and Japan under the brand name LORBRE...

Collaboration on Developing First-in-Class Therapeutics for NSCLC

SK Biopharmaceuticals, a pharmaceutical company focused on disorders of central nervous system and cancer, and twoXAR, Inc., an artificial intelligence (AI)-driven biopharmaceutical company, announced...

Benefits of Risk-Share Arrangements

Value in Health, the official journal of ISPOR—the professional society for health economics and outcomes research, announced the publication of new research showing that pharmaceutical risk-sharing a...

EC Approved Keytruda in Combination with Chemotherapy

KEYTRUDA is First Anti-PD-1 Therapy Approved in Combination with Chemotherapy in Europe for Adults with Metastatic Squamous NSCLC Regardless of PD-L1 Expression. Merck, known as MSD outside the Uni...

Pfizer Received Positive CHMP Opinion for NSCLC Treatment

pfizer
Pfizer announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for LORVIQUA® (lorlatinib, approved in the U.S., C...

CHMP Accepts Roche’s NSCLC Drug

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Roche's Tecentriq (tezolizumab) - a monoclonal antibody designed to bind with a protei...

Roche Has to Wait for FDA Decision for NSCLC Drug

Roche will wait until September 2019 for the FDA’s decision, before it can combine Tecentriq with Abraxane and carboplatin for the first-line treatment of lung cancer patients, who don’t have EGFR or ...